Covalent Conjugation of Amphotericin B to Hyaluronic Acid: An Injectable Water-Soluble Conjugate with Reduced Toxicity and Anti-Leishmanial Potential

Silva-Carvalho, Ricardo; Leão, Teresa; Gama, Miguel; Tomás, Ana M.

doi:10.1021/acs.biomac.1c01451

Cited by 7 publications

(2 citation statements)

References 84 publications

(157 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pentavalent antimonial is the first-line drug for treating visceral leishmaniasis, but its adverse events or toxic reactions happen frequently, and even ineffective reactions occur [ 51 ]. Amphotericin B, a polyene macrolide antibiotic that binds to sterols in cell membranes, is currently the most effective anti-leishmanial drug [ 52 ]. Due to its poor oral absorption, only dosing concentrations can be achieved by intravenous injection.…”

Section: Liposomes and Lipid Nanoparticles (Lnps)mentioning

confidence: 99%

Approved Nanomedicine against Diseases

Jia

Jiang

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Nanomedicine is a branch of medicine using nanotechnology to prevent and treat diseases. Nanotechnology represents one of the most effective approaches in elevating a drug‘s treatment efficacy and reducing toxicity by improving drug solubility, altering biodistribution, and controlling the release. The development of nanotechnology and materials has brought a profound revolution to medicine, significantly affecting the treatment of various major diseases such as cancer, injection, and cardiovascular diseases. Nanomedicine has experienced explosive growth in the past few years. Although the clinical transition of nanomedicine is not very satisfactory, traditional drugs still occupy a dominant position in formulation development, but increasingly active drugs have adopted nanoscale forms to limit side effects and improve efficacy. The review summarized the approved nanomedicine, its indications, and the properties of commonly used nanocarriers and nanotechnology.

show abstract

Section: Liposomes and Lipid Nanoparticles (Lnps)mentioning

confidence: 99%

Approved Nanomedicine against Diseases

Jia

Jiang

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…In the delivery of antileishmanial drugs to macrophages, a nanocarrier should be capable of delivering the active moiety at the targeted site in macrophages. Most frequently used nanoparticles in macrophage targeting through IV route are liposomes, non-ionic surfactant vesicles, nano emulsions and nano discs, where liposome lipid carriers are the most frequently employed for delivery of anti-leishmania drugs (Silva-Carvalho et al, 2022).…”

Section: Introductionmentioning

confidence: 99%

Design, development and formulation of Miltefosine loaded Mannosylated Liposomes for Anti-leishmanial activity

Chourasiya,

Singhai,

Jain

et al. 2023

Adv Pharma J

View full text Add to dashboard Cite

Conventional drug delivery systems utilized in the treatment of Leishmaniasis extend a number of drawbacks such as nephrotoxicity, GIT disturbance, methaemoglobinaemia etc. and have limited utility because anti-leishmaniasis therapeutics in such system lack efficient selectivity towards macrophages cells in RES. The main objective of present study is to design carrier systems in which mannose engineered liposomes was encapsulated with antileishmanial drug i.e., Miltefosine. Drug loaded liposomes were prepared by a cast film method using PC cholesterol, sterylamine, P-aminophenyl-a-D-mannoside. For mannose coupled liposomes, the PC: CH ratio with respect to SA was found to be 7:3:1.5 with maximum entrapment efficiency of 65.32 ± 3.3%. The encapsulation efficiency was determined by centrifugation method. It was found to be 40.15 ± 2.2% for LIP3C* whereas it was 39.12% for LIP3C-M* (mannose coupled). The drug release from uncoupled and coupled liposomes was studied in PBS (pH in vitro 7.4) using dialysis tube and cellophane membrane. The percentage drug release was found to be 45.7% for LIP3C* (cationic) while it was 41.9% for LIP3C-M* (mannose coupled) after 24 hours.

show abstract